Biologics Competition Act of 2023

Bill 118 hr 1790, also known as the Biologics Competition Act of 2023, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to promote competition in the biologics market, which are complex drugs made from living organisms.

The Biologics Competition Act of 2023 aims to increase access to lower-cost biologic drugs by allowing for the approval of biosimilar products, which are similar to existing biologics but are not identical. This would create more options for patients and potentially drive down prices through increased competition.

Additionally, the bill includes provisions to streamline the approval process for biosimilar products, making it easier for these drugs to come to market. This could help to speed up the availability of lower-cost alternatives to expensive biologics. Overall, the Biologics Competition Act of 2023 is focused on increasing competition in the biologics market in order to make these important drugs more affordable and accessible to patients. It will be interesting to see how this legislation progresses through Congress and what impact it may have on the healthcare industry.